Package Leaflet: Information for the Patient
Almotriptan Stada 12.5 mg Film-Coated Tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet:
Almotriptan Stada is an antimigraine medication that belongs to a class of compounds known as selective serotonin receptor agonists. It is believed that almotriptan reduces the inflammatory response associated with migraines by binding to serotonin receptors in cerebral blood vessels (cranial), causing vasoconstriction.
Almotriptan is used to relieve headache pain associated with migraine attacks with or without aura.
Do not take Almotriptan Stada:
Warnings and precautions
Consult your doctor or pharmacist before starting to take almotriptan:
It has been suggested that excessive use of antimigraine medications may lead to chronic headache.
Children and adolescents
Children under 18 years old should not take almotriptan.
Elderly (over 65 years old)
If you are over 65 years old, you should consult your doctor before taking this medication.
Taking Almotriptan Stada with other medications
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medications.
Please inform your doctor:
Almotriptan should not be taken at the same time as other medications that contain ergotamine, which are also used to treat migraines. However, both medications can be taken one after the other, provided that a minimum amount of time has passed between doses:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Only very limited information is available on the use of almotriptan during pregnancy. Almotriptan STADA should only be used during pregnancy if prescribed by your doctor and only after carefully considering the balance between the benefits and risks.
Caution should be exercised when using this medication during breastfeeding. You should avoid breastfeeding during the 24 hours following treatment.
Driving and using machines
Almotriptan Stada may cause drowsiness. If you experience this, do not drive or use tools or machines.
Almotriptan Stada contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Almotriptan should only be used to treat a migraine attack that has already occurred and not to prevent migraine attacks or headaches.
Adults (18-65 years old)
The recommended dose is one 12.5 mg tablet, which should be taken as soon as possible after the onset of the migraine attack. If the attack does not subside, do not take more than one tablet for the same attack.
If you experience a second attack within the next 24 hours, a second 12.5 mg tablet can be taken, but always provided that at least 2 hours have passed between the first and second tablets.
The maximum daily dose is two tablets (12.5 mg) in 24 hours.
The tablet should be swallowed with liquid (e.g., water) and can be taken with or without food.
You should take almotriptan as soon as possible after the onset of a migraine attack, although it is also effective if taken later.
Severe kidney disease
If you have severe kidney disease, do not take more than one 12.5 mg tablet in 24 hours.
If you take more Almotriptan Stada than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service (telephone 91 562 04 20), indicating the medication and the amount taken.
If you forget to take Almotriptan Stada
Try to take almotriptan as prescribed. Do not take a double dose to make up for forgotten doses.
If you have any further questions on the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medication can cause side effects, although not everybody gets them.
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 10,000 people)
Frequency not known(cannot be estimated from the available data)
During treatment with almotriptan, inform your doctor immediately:
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiry date which is stated on the packaging after “EXP”. The expiry date is the last day of the month shown.
This medication does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Almotriptan Stada
Core of the tablet:mannitol (E-421), microcrystalline cellulose, povidone, sodium starch glycolate Type A potato, and sodium stearyl fumarate.
Coating material:hypromellose (E-464), titanium dioxide (E-171), macrogol 400, and carnauba wax.
Appearance of the product and contents of the pack
Almotriptan Stada are white, circular, and biconvex film-coated tablets.
Almotriptan Stada is available in packs of 2, 3, 4, 6, 9, 12, or 14 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Laboratory STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Manufacturer
Chanelle Medical Unlimited Company
Dublin Road, Loughrea, H62 FH90
Ireland
Date of last revision of this leaflet:July 2021
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of ALMOTRIPTAN STADA 12.5 mg FILM-COATED TABLETS in October, 2025 is around 19.53 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.